

- **Name:** Joon Seong Park
  - **Current Position & Affiliation:** Professor of Hepatobiliary Pancreas Cancer Clinic,  
Department of Surgery, Gangnam Severance Hospital,  
Yonsei University
  - **Country:** Republic of Korea
- 

**• Educational Background:**

- 2007 - 2011 Yonsei University (Ph.D)
- 2001 - 2006 Yonsei University (Master)
- 1991 - 1997 Yonsei University College of Medicine (M.D)

**• Professional Experience:**

- 2017 - Present Professor of Surgery, Gangnam Severance Hospital, Yonsei University
- 2012 - 2016 Associate Professor of Surgery, Gangnam Severance Hospital, Yonsei University
- 2012 - 2014 Visiting Professor, Pancreas Cancer Research, Department of Surgery, University of Minnesota, MN, USA
- 2007 - 2011 Assistant Professor of Surgery, Gangnam Severance Hospital, Yonsei University
- 2005 - 2006 Clinical Fellow, Hepatobiliary Pancreas surgery, Gangnam Severance Hospital

**• Professional Organizations:**

- Yonsei University

**• Main Scientific Publications:**

As an oncological surgeon-scientist, I was trained in Cancer Biology for studying pancreatic cancer and translational medicine. Based on more than 15 years of clinical experience in treating HBP cancer patients, now I am developing molecular diagnostics which is clinically usable to identify distinct prognostic and predictive subgroups to particular treatment within the identical clinical stage. The overarching goal of my research is to identify potential diagnostic and therapeutic targets and to develop clinical relevant prognostic or predictive markers as well as valid targets for novel therapeutics. To this end, I have been collaborating with a number of researchers in diverse discipline: cell biology, molecular biology, pathology and engineering etc. This trans-disciplinary approach utilizes patient-derived resources to accurately model human cancer molecular pathophysiology to bridge the preclinical and the clinic. To clinical tumor repository, we have established Patient-Derived

tumor xenograft (PDX) and Organic models. Based on these platforms, I orchestrate novel cancer therapeutics development specially for therapy refractory pancreatic cancers.